The webinar will feature a fireside chat with Key Opinion Leader (KOL) Jeffrey Miller, M.D. and CytoImmune’s Co-Founder Michael Caligiuri, M.D. who will discuss CytoImmune’s approach for human natural killer (NK) cell immunotherapy with a heavy focus on programmed death-ligand 1 (PD-L1)+ NK cell for use in treating lung cancer, and fms-like tyrosine kinase 3 (FLT3) CAR NK cell therapy for use in treating Acute Myeloid Leukemia (AML). Dr. Miller and Dr. Caligiuri will be available to answer questions at the conclusion of the event.

CytoImmune is currently developing an approach for human natural killer (NK) cell immunotherapy that involves an off-the-shelf CAR NK cell that enables the cell to recognize specific proteins or antigens that are present on the surface of tumor cells and is approaching the clinic in 2021 with lead target FLT-3 in AML.